SCHEMBL13367649

SCHEMBL13367649

COc1ccc(-c2csc(C)n2)cc1F

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.74
SMN1; SMN2 Q16637 7/20 0.74
NPC1 O15118 6/20 0.74
RAB9A P51151 6/20 0.74
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
MAPT P10636 4/20 0.69
RECQL P46063 3/20 0.65
GAA P10253 3/20 0.65
GFER P55789 1/20 0.65
PTGES O14684 1/20 0.54
KDM4E B2RXH2 4/20 0.53
POLB P06746 2/20 0.53
HPGD P15428 2/20 0.53
ESR2 Q92731 1/20 0.53
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6040790 0.86 MAPT (0.75) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL1802287 0.85 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL19625303 0.84 RAB9A (0.68) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL1764691 0.82 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL8083706 0.82 MAPT (0.69) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL19626555 0.82 MAPT (0.69) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL13341097 0.81 RAB9A (0.68) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL1765099 0.81 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL19626653 0.79 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7811998 0.78 MAPT (0.64) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-11-23 US disclosed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators WNT1, WNT3A, CTNNB1 ALDH1A1 1166/4885SMN1; SMN2 4828/4885NPC1 2489/4885
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ ALDH1A1 3843/4885SMN1; SMN2 2625/4885NPC1 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.